Skip to main content
Erschienen in:

01.03.2010 | Leitthema

Supportive Therapie bei multiplem Myelom

verfasst von: Dr. N. Zojer, H. Ludwig

Erschienen in: Die Onkologie | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das multiple Myelom kann durch Knochenzerstörung, Beeinträchtigung der Hämatopoese und der Nierenfunktion sowie durch Verursachung einer Infektneigung oder erhöhter Serumkalziumwerte zu einer vielfältigen Symptomatik führen. Diese Manifestationen auf Organebene beeinträchtigen naturgemäß auch das Wohlbefinden des Patienten. Eine grundlegende Einschränkung der Lebensqualität durch Komplikationen der Grunderkrankung oder Nebenwirkungen der Therapie kann sowohl auf der physischen, emotionalen als auch der psychosozialen Ebene manifest werden. Zu wesentlichen Supportivmaßnahmen bei Myelomerkrankung zählt die Prophylaxe und Behandlung von Knochendestruktion, Hyperkalzämie und Anämie, die Behandlung von Schmerzen und Infektionen, die Prophylaxe von Infektkomplikationen und thromboembolischen Ereignissen, letztere speziell auch bei Therapieregimen unter Einschluss immunomodulatorischer Substanzen. Im Folgenden werden wichtige Prinzipien der Supportivtherapie beim multiplen Myelom behandelt.
Literatur
1.
Zurück zum Zitat Kyle RA (1975) Multiple myeloma, review of 869 cases. Mayo Clin Proc 50:29–40PubMed Kyle RA (1975) Multiple myeloma, review of 869 cases. Mayo Clin Proc 50:29–40PubMed
2.
Zurück zum Zitat Terpos E, Dimopoulos MA (2005) Myeloma bone disease: pathophysiology and management. Ann Oncol 16(8):1223–1231CrossRefPubMed Terpos E, Dimopoulos MA (2005) Myeloma bone disease: pathophysiology and management. Ann Oncol 16(8):1223–1231CrossRefPubMed
3.
Zurück zum Zitat Bataille R, Manolagas SC, Berenson JR (1997) Pathogenesis and management of bone lesions in multiple myeloma. In: Hematol Oncol Clin North Am 11:349–61 Bataille R, Manolagas SC, Berenson JR (1997) Pathogenesis and management of bone lesions in multiple myeloma. In: Hematol Oncol Clin North Am 11:349–61
4.
Zurück zum Zitat Hussein MA, Vrionis FD, Allison R et al (2008) International Myeloma Working Group. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 22(8):1479–1484CrossRefPubMed Hussein MA, Vrionis FD, Allison R et al (2008) International Myeloma Working Group. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 22(8):1479–1484CrossRefPubMed
5.
Zurück zum Zitat Belch AR, Bergsagel DE, Wilson K et al (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9(8):1397–1402PubMed Belch AR, Bergsagel DE, Wilson K et al (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9(8):1397–1402PubMed
6.
Zurück zum Zitat Daragon A, Humez C, Michot C et al (1993) Treatment of multiple myeloma with etidronate: results of a multicenter double-blind study. Groupe d’Etudes et de Recherches sur le Myélome (GERM). Eur J Med 2(8):449–452PubMed Daragon A, Humez C, Michot C et al (1993) Treatment of multiple myeloma with etidronate: results of a multicenter double-blind study. Groupe d’Etudes et de Recherches sur le Myélome (GERM). Eur J Med 2(8):449–452PubMed
7.
Zurück zum Zitat Lahtinen R, Laakso M, Palva I et al (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049–1052CrossRefPubMed Lahtinen R, Laakso M, Palva I et al (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049–1052CrossRefPubMed
8.
Zurück zum Zitat McCloskey EV, MacLennan IC, Drayson MT et al (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317–325CrossRefPubMed McCloskey EV, MacLennan IC, Drayson MT et al (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317–325CrossRefPubMed
9.
Zurück zum Zitat Berenson JR, Lichtenstein A, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488–493CrossRefPubMed Berenson JR, Lichtenstein A, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488–493CrossRefPubMed
10.
Zurück zum Zitat Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593–602PubMed Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593–602PubMed
11.
Zurück zum Zitat Attal M, Harousseau JL, Leyvraz S et al (2006) Inter-Groupe Francophone du Myelome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294CrossRefPubMed Attal M, Harousseau JL, Leyvraz S et al (2006) Inter-Groupe Francophone du Myelome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294CrossRefPubMed
12.
Zurück zum Zitat Berenson JR, Rosen LS, Howell A et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191–1200CrossRefPubMed Berenson JR, Rosen LS, Howell A et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191–1200CrossRefPubMed
13.
Zurück zum Zitat Rosen LS, Gordon D, Kaminski M et al (n d) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387 Rosen LS, Gordon D, Kaminski M et al (n d) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387
14.
Zurück zum Zitat Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744CrossRefPubMed Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744CrossRefPubMed
15.
Zurück zum Zitat Terpos E, Viniou N, Fuente J de la et al (2003) Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 70(1):34–42CrossRefPubMed Terpos E, Viniou N, Fuente J de la et al (2003) Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 70(1):34–42CrossRefPubMed
16.
Zurück zum Zitat Menssen HD, Sakalova A, Fontana A et al (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20(9):2353–2359CrossRefPubMed Menssen HD, Sakalova A, Fontana A et al (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20(9):2353–2359CrossRefPubMed
17.
Zurück zum Zitat Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353(1):99–102CrossRefPubMed Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353(1):99–102CrossRefPubMed
18.
Zurück zum Zitat Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580–8587CrossRefPubMed Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580–8587CrossRefPubMed
19.
Zurück zum Zitat Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464–2472CrossRefPubMed Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464–2472CrossRefPubMed
20.
Zurück zum Zitat Anderson KC and NCCN Multiple Myeloma Panel Members. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 2–2009. http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf Anderson KC and NCCN Multiple Myeloma Panel Members. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 2–2009. http://​www.​nccn.​org/​professionals/​physician_​gls/​PDF/​myeloma.​pdf
21.
Zurück zum Zitat Lacy MQ, Dispenzieri A, Gertz MA et al (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81(8):1047–1053CrossRefPubMed Lacy MQ, Dispenzieri A, Gertz MA et al (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81(8):1047–1053CrossRefPubMed
22.
Zurück zum Zitat Harousseau JL, Dreyling M (2008) On behalf of the ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 19 (Supplement 2): ii55–ii57CrossRefPubMed Harousseau JL, Dreyling M (2008) On behalf of the ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 19 (Supplement 2): ii55–ii57CrossRefPubMed
23.
Zurück zum Zitat Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82(4):516–517; author reply 517–518CrossRefPubMed Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82(4):516–517; author reply 517–518CrossRefPubMed
24.
Zurück zum Zitat Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20(8):1303–1317CrossRefPubMed Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20(8):1303–1317CrossRefPubMed
25.
Zurück zum Zitat Pecherstorfer M, Brenner K, Zojer N (2003) Current management strategies for hypercalcemia. Treat Endocrinol 2(4):273–292. ReviewCrossRefPubMed Pecherstorfer M, Brenner K, Zojer N (2003) Current management strategies for hypercalcemia. Treat Endocrinol 2(4):273–292. ReviewCrossRefPubMed
26.
Zurück zum Zitat Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322(24):1693–1699PubMed Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322(24):1693–1699PubMed
27.
Zurück zum Zitat Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172–179CrossRefPubMed Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172–179CrossRefPubMed
28.
Zurück zum Zitat Garton JP, Gertz MA, Witzig TE et al (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155:2069–2074CrossRefPubMed Garton JP, Gertz MA, Witzig TE et al (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155:2069–2074CrossRefPubMed
29.
Zurück zum Zitat Dammacco F, Silvestris F, Castoldi GL et al (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127–134CrossRefPubMed Dammacco F, Silvestris F, Castoldi GL et al (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127–134CrossRefPubMed
30.
Zurück zum Zitat Osterborg A, Boogaerts MA, Cimino R et al (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma – a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 87:2675–2682PubMed Osterborg A, Boogaerts MA, Cimino R et al (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma – a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 87:2675–2682PubMed
31.
Zurück zum Zitat Cazzola M, Messinger D, Battistel V et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86:4446–4453PubMed Cazzola M, Messinger D, Battistel V et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86:4446–4453PubMed
32.
Zurück zum Zitat Silvestris F, Romito A, Fanelli P et al (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313–318CrossRefPubMed Silvestris F, Romito A, Fanelli P et al (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313–318CrossRefPubMed
33.
Zurück zum Zitat Osterborg A, Brandberg Y, Molostova V et al (2002) Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20:2486–2494CrossRefPubMed Osterborg A, Brandberg Y, Molostova V et al (2002) Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20:2486–2494CrossRefPubMed
34.
Zurück zum Zitat Hedenus M, Adriansson M, San Miguel J et al (2003) Darbepoetin Alfa 20000161 Study Efficacy and safety of darbepoetin alfa in anaemic patients withlymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122(3):394–403CrossRefPubMed Hedenus M, Adriansson M, San Miguel J et al (2003) Darbepoetin Alfa 20000161 Study Efficacy and safety of darbepoetin alfa in anaemic patients withlymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122(3):394–403CrossRefPubMed
35.
Zurück zum Zitat Cazzola M, Beguin Y, Kloczko J et al (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122(3):386–393CrossRefPubMed Cazzola M, Beguin Y, Kloczko J et al (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122(3):386–393CrossRefPubMed
36.
Zurück zum Zitat Musto P, Falcone A, D’Arena G et al (1997) Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 58:314–319PubMedCrossRef Musto P, Falcone A, D’Arena G et al (1997) Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 58:314–319PubMedCrossRef
37.
Zurück zum Zitat Rizzo JD, Somerfield MR, Hagerty KL et al (2008) American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26(1):132–49. Epub 2007 Oct 22. Erratum in: J Clin Oncol. 2008 Mar 1;26(7):1192 Rizzo JD, Somerfield MR, Hagerty KL et al (2008) American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26(1):132–49. Epub 2007 Oct 22. Erratum in: J Clin Oncol. 2008 Mar 1;26(7):1192
38.
Zurück zum Zitat Bokemeyer C, Aapro MS, Courdi A et al (2007) European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–70. Epub 2006 Dec 19. ReviewCrossRefPubMed Bokemeyer C, Aapro MS, Courdi A et al (2007) European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–70. Epub 2006 Dec 19. ReviewCrossRefPubMed
39.
Zurück zum Zitat Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist (Suppl 13) 3:33–36 Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist (Suppl 13) 3:33–36
40.
Zurück zum Zitat Greil R, Psenak O, Roila F (2008) ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol (Suppl 19) 2:ii116– ii118 Greil R, Psenak O, Roila F (2008) ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol (Suppl 19) 2:ii116– ii118
41.
Zurück zum Zitat Osterborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129(2):206–209CrossRefPubMed Osterborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129(2):206–209CrossRefPubMed
42.
Zurück zum Zitat Ludwig H (2006) Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol 43(4 Suppl 6):S13–17CrossRef Ludwig H (2006) Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol 43(4 Suppl 6):S13–17CrossRef
43.
Zurück zum Zitat Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.J Natl Cancer Inst 98(10):708–714PubMedCrossRef Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.J Natl Cancer Inst 98(10):708–714PubMedCrossRef
44.
Zurück zum Zitat Baz R, Walker E, Choueiri TK et al (2007) Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 117(3):162–167CrossRefPubMed Baz R, Walker E, Choueiri TK et al (2007) Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 117(3):162–167CrossRefPubMed
45.
Zurück zum Zitat Katodritou E, Verrou E, Hadjiaggelidou C et al (2008) Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 83(9):697–701CrossRefPubMed Katodritou E, Verrou E, Hadjiaggelidou C et al (2008) Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 83(9):697–701CrossRefPubMed
46.
Zurück zum Zitat Richardson P, Schlag R, Khuageva NK et al (2008) Erythropoiesis-Stimulating agents do not adversely Affect long-term outcomes nor increase the risk of tromboembolic events in mltiple meloma ptients teated in the pase III VISTA Trial. Blood (ASH Annual Meeting Abstracts), 112:1741 Richardson P, Schlag R, Khuageva NK et al (2008) Erythropoiesis-Stimulating agents do not adversely Affect long-term outcomes nor increase the risk of tromboembolic events in mltiple meloma ptients teated in the pase III VISTA Trial. Blood (ASH Annual Meeting Abstracts), 112:1741
47.
Zurück zum Zitat Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535–2542CrossRefPubMed Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535–2542CrossRefPubMed
48.
Zurück zum Zitat Crawford J, Cella D, Cleeland CS et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95(4):888–895CrossRefPubMed Crawford J, Cella D, Cleeland CS et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95(4):888–895CrossRefPubMed
49.
Zurück zum Zitat Chapel HM, Lee M, Hargreaves R et al (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059–1063CrossRefPubMed Chapel HM, Lee M, Hargreaves R et al (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059–1063CrossRefPubMed
50.
Zurück zum Zitat Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100:624–628CrossRefPubMed Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100:624–628CrossRefPubMed
51.
Zurück zum Zitat Cullen M, Steven N, Billingham L et al (2005) Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988–998CrossRefPubMed Cullen M, Steven N, Billingham L et al (2005) Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988–998CrossRefPubMed
52.
Zurück zum Zitat Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205CrossRefPubMed Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205CrossRefPubMed
53.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158–3167CrossRefPubMed Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158–3167CrossRefPubMed
54.
Zurück zum Zitat Singhal S, Mehta J (1999) Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 23(7):637–646CrossRefPubMed Singhal S, Mehta J (1999) Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 23(7):637–646CrossRefPubMed
55.
Zurück zum Zitat Robertson JD, Nagesh K, Jowitt SN et al (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82(7):1261–1265CrossRefPubMed Robertson JD, Nagesh K, Jowitt SN et al (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82(7):1261–1265CrossRefPubMed
56.
Zurück zum Zitat Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: A systematic review of the literature with meta-analysis. Support Care Cancer 10:181–188CrossRefPubMed Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: A systematic review of the literature with meta-analysis. Support Care Cancer 10:181–188CrossRefPubMed
57.
Zurück zum Zitat Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214CrossRefPubMed Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214CrossRefPubMed
58.
Zurück zum Zitat Grossman SA, Sheidler VR, Swedeen K et al (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Sympt Manage 6: 53–57CrossRef Grossman SA, Sheidler VR, Swedeen K et al (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Sympt Manage 6: 53–57CrossRef
59.
Zurück zum Zitat Grossman SA (1993) Undertreatment of cancer pain: barriers and remedies. Support Care Cancer 1:74–78CrossRefPubMed Grossman SA (1993) Undertreatment of cancer pain: barriers and remedies. Support Care Cancer 1:74–78CrossRefPubMed
60.
Zurück zum Zitat Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18(4):673–688CrossRefPubMed Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18(4):673–688CrossRefPubMed
61.
Zurück zum Zitat Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24(27):4507–4514CrossRefPubMed Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24(27):4507–4514CrossRefPubMed
62.
Zurück zum Zitat Palumbo A, Facon T, Sonneveld P et al (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111(8):3968–3977CrossRefPubMed Palumbo A, Facon T, Sonneveld P et al (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111(8):3968–3977CrossRefPubMed
63.
Zurück zum Zitat Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113–3120CrossRefPubMed Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113–3120CrossRefPubMed
64.
Zurück zum Zitat Richardson PG, Sonneveld P, Schuster MW et al (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903CrossRefPubMed Richardson PG, Sonneveld P, Schuster MW et al (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903CrossRefPubMed
65.
Zurück zum Zitat Palumbo AP, Bringhen S, Rossi D et al (2009) Italian Multiple Myeloma Network (GIMEMA). A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. J Clin Oncol 27:15 s (suppl; abstr 8515)CrossRef Palumbo AP, Bringhen S, Rossi D et al (2009) Italian Multiple Myeloma Network (GIMEMA). A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. J Clin Oncol 27:15 s (suppl; abstr 8515)CrossRef
66.
Zurück zum Zitat Racz I, Nadal X, Alferink J et al (2008) Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28(46):12125–12135CrossRefPubMed Racz I, Nadal X, Alferink J et al (2008) Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28(46):12125–12135CrossRefPubMed
67.
Zurück zum Zitat Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634CrossRefPubMed Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634CrossRefPubMed
68.
Zurück zum Zitat Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505CrossRefPubMed Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505CrossRefPubMed
69.
Zurück zum Zitat Siragusa S, Cosmi B, Piovella F et al (1996) Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100(3):269–277CrossRefPubMed Siragusa S, Cosmi B, Piovella F et al (1996) Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100(3):269–277CrossRefPubMed
70.
Zurück zum Zitat Lee AY, Levine MN, Baker RI et al (2003) Randomized cmparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153CrossRefPubMed Lee AY, Levine MN, Baker RI et al (2003) Randomized cmparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153CrossRefPubMed
71.
Zurück zum Zitat Srkalovic G, Cameron MG, Rybicki L et al (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101(3):558–566CrossRefPubMed Srkalovic G, Cameron MG, Rybicki L et al (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101(3):558–566CrossRefPubMed
72.
Zurück zum Zitat Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423CrossRefPubMed Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423CrossRefPubMed
73.
Zurück zum Zitat Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1568–1574CrossRefPubMed Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1568–1574CrossRefPubMed
74.
Zurück zum Zitat Rajkumar SV, Jacobus S, Callander N et al (2007) Greipp P Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), LBA8025 Rajkumar SV, Jacobus S, Callander N et al (2007) Greipp P Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), LBA8025
75.
Zurück zum Zitat Palumbo A, Falco P, Corradini P et al (2007) GIMEMA–Italian multiple myeloma network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol 25(28):4459–4465CrossRefPubMed Palumbo A, Falco P, Corradini P et al (2007) GIMEMA–Italian multiple myeloma network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol 25(28):4459–4465CrossRefPubMed
76.
Zurück zum Zitat Baz R, Walker E, Karam MA et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17(12):1766–1771CrossRefPubMed Baz R, Walker E, Karam MA et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17(12):1766–1771CrossRefPubMed
77.
Zurück zum Zitat Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19CrossRefPubMed Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19CrossRefPubMed
78.
Zurück zum Zitat Cavo M, Zamagni E, Tosi P et al (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89(7):826–831PubMed Cavo M, Zamagni E, Tosi P et al (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89(7):826–831PubMed
79.
Zurück zum Zitat Offidani M, Corvatta L, Piersantelli MN et al (2006) Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 108(7):2159–2164CrossRefPubMed Offidani M, Corvatta L, Piersantelli MN et al (2006) Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 108(7):2159–2164CrossRefPubMed
80.
Zurück zum Zitat Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126(5):715–721CrossRefPubMed Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126(5):715–721CrossRefPubMed
81.
Zurück zum Zitat Palumbo A, Bringhen S, Caravita T et al (2006) Italian multiple myeloma network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825–831CrossRefPubMed Palumbo A, Bringhen S, Caravita T et al (2006) Italian multiple myeloma network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825–831CrossRefPubMed
Metadaten
Titel
Supportive Therapie bei multiplem Myelom
verfasst von
Dr. N. Zojer
H. Ludwig
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 3/2010
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-010-1793-y

Weitere Artikel der Ausgabe 3/2010

Der Onkologe 3/2010 Zur Ausgabe

In der Diskussion: Komplementäre Onkologie

Vitamin C in der komplementären Onkologie

CME Weiterbildung · Zertifizierte Fortbildung

Chirurgie der Schilddrüsenkarzinome

Neu im Fachgebiet Onkologie

Tisotumab-Vedotin verlängert Überleben nach Zervixkarzinom-Rezidiv

13.07.2024 Zervixkarzinom Nachrichten

Für Frauen mit rezidiviertem oder metastasiertem Zervixkarzinom und Versagen der Erstlinientherapie zeichnet sich eine Verbesserung der Behandlungsoptionen ab: Mit dem Antikörper-Wirkstoff-Konjugat Tisotumab-Vedotin überleben sie zwei Monate länger als mit einer Chemotherapie.

Was das Überwachen von Risikopersonen für Pankreaskrebs bringt

12.07.2024 Pankreaskarzinom Nachrichten

Programme zur Überwachung von Hochrisikokandidaten für duktales Adenokarzinom des Pankreas führen womöglich zu früherer Diagnose. Ob sich das auch in einem Überlebensvorteil niederschlägt, hat eine Studie getestet.

Prostatakarzinome der ISUP-Gruppe 1 nicht immer harmlos

11.07.2024 Prostatakarzinom Nachrichten

Nicht bei allen Prostatakarzinomen der Gleason-Graduierungsgruppe 1 kann man davon ausgehen, dass sie benigne sind. In einer Studie aus dem UKE Hamburg hatten auch in dieser Gruppe bestimmte Patienten ein deutlich erhöhtes Risiko für einen ungünstigen Verlauf.

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.